At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Panobinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Mar 30, 2016·Updated Nov 1, 2022
In Brief
A Phase 2 clinical trial evaluating Panobinostat for Multiple Myeloma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and tolerability of LBH589 maintenance therapy after autologous hematopoietic cell transplant (HCT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartJun 2016
Primary CompletionJun 2020
Study CompletionJan 2021
TodayJul 2026
First PostedMar 30, 2016
Enrollment StartJun 10, 2016
Primary CompletionJun 7, 2020
Study CompletionJan 18, 2021
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 10.3 years ago
Interventions
Panobinostatdrug
Maintenance therapy dosing as outlined in Cohorts A and B.